EULAR Updates Behçet’s Syndrome Recommendations
EULAR releases updated recommendations supporting earlier biologic use in patients with eye, vascular, and nervous system involvement
By
Kathryn Wighton
April 1, 2026
1
EULAR updated its Behçet’s syndrome management recommendations, emphasizing earlier biologic use for severe organ involvement.
2
Colchicine remains the first-line treatment for mucocutaneous involvement, with alternatives like apremilast for refractory cases.
3
For Behçet’s uveitis, immunosuppressive treatment is essential, with infliximab preferred for sight-threatening inflammation.
4
The task force recommends high-dose glucocorticoids plus infliximab for arterial involvement, reflecting new evidence supporting this approach.
5
The recommendations highlight the need for individualized treatment and multidisciplinary care to maximize patient quality of life.
